AU757406B2 - Methods and compositions for stimulating neurite growth - Google Patents
Methods and compositions for stimulating neurite growth Download PDFInfo
- Publication number
- AU757406B2 AU757406B2 AU43801/00A AU4380100A AU757406B2 AU 757406 B2 AU757406 B2 AU 757406B2 AU 43801/00 A AU43801/00 A AU 43801/00A AU 4380100 A AU4380100 A AU 4380100A AU 757406 B2 AU757406 B2 AU 757406B2
- Authority
- AU
- Australia
- Prior art keywords
- straight
- branched
- alkyl
- alkenyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 48
- 230000014511 neuron projection development Effects 0.000 title claims description 29
- 230000004936 stimulating effect Effects 0.000 title claims description 19
- -1 2-indolyl Chemical group 0.000 claims description 217
- 125000000217 alkyl group Chemical group 0.000 claims description 171
- 125000003342 alkenyl group Chemical group 0.000 claims description 155
- 239000001257 hydrogen Substances 0.000 claims description 112
- 229910052739 hydrogen Inorganic materials 0.000 claims description 112
- 150000001875 compounds Chemical class 0.000 claims description 104
- 229910052760 oxygen Inorganic materials 0.000 claims description 77
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 73
- 125000000304 alkynyl group Chemical group 0.000 claims description 60
- 125000001424 substituent group Chemical group 0.000 claims description 53
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 49
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 45
- 239000001301 oxygen Substances 0.000 claims description 45
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims description 37
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 37
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 32
- 239000003900 neurotrophic factor Substances 0.000 claims description 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 31
- 230000000508 neurotrophic effect Effects 0.000 claims description 31
- 125000006709 (C5-C7) cycloalkenyl group Chemical group 0.000 claims description 30
- 125000005842 heteroatom Chemical group 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 29
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 29
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 28
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 27
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 210000002569 neuron Anatomy 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 20
- 125000001041 indolyl group Chemical group 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 17
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 16
- 229940053128 nerve growth factor Drugs 0.000 claims description 16
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 14
- 150000001721 carbon Chemical group 0.000 claims description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000000335 thiazolyl group Chemical group 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 11
- 150000003857 carboxamides Chemical class 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 9
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 9
- 125000003828 azulenyl group Chemical group 0.000 claims description 9
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 8
- IIBOGKHTXBPGEI-UHFFFAOYSA-N N-benzylformamide Chemical compound O=CNCC1=CC=CC=C1 IIBOGKHTXBPGEI-UHFFFAOYSA-N 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- NOQAFHBELOIHBE-UHFFFAOYSA-N n-formylpyridine-2-carboxamide Chemical compound O=CNC(=O)C1=CC=CC=N1 NOQAFHBELOIHBE-UHFFFAOYSA-N 0.000 claims description 8
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 7
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 7
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 7
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 7
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 7
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 7
- 125000005805 dimethoxy phenyl group Chemical group 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 7
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 7
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 7
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- ZPQHRYDGTIMVKO-UHFFFAOYSA-N n-morpholin-4-ylformamide Chemical compound O=CNN1CCOCC1 ZPQHRYDGTIMVKO-UHFFFAOYSA-N 0.000 claims description 7
- 230000001537 neural effect Effects 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims description 7
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 7
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims description 7
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 7
- 125000005936 piperidyl group Chemical group 0.000 claims description 7
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 7
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 6
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 6
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 6
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 6
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 6
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 6
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 6
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- HTHDQCIQHNPBNB-UHFFFAOYSA-N n-thiomorpholin-4-ylformamide Chemical compound O=CNN1CCSCC1 HTHDQCIQHNPBNB-UHFFFAOYSA-N 0.000 claims description 6
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 6
- 125000001680 trimethoxyphenyl group Chemical group 0.000 claims description 6
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims description 5
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 5
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 3
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000003683 Neurotrophin-4 Human genes 0.000 claims description 3
- 102100033857 Neurotrophin-4 Human genes 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 230000001886 ciliary effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000000256 facial nerve Anatomy 0.000 claims description 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 229940097998 neurotrophin 4 Drugs 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000005412 pyrazyl group Chemical group 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 2
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 53
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims 30
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims 30
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 6
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 claims 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 102000004230 Neurotrophin 3 Human genes 0.000 claims 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 241001559589 Cullen Species 0.000 claims 1
- 244000304337 Cuminum cyminum Species 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 claims 1
- 125000006502 nitrobenzyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 8
- 229960002930 sirolimus Drugs 0.000 description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 6
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108090000317 Chymotrypsin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229960002376 chymotrypsin Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000000521 Immunophilins Human genes 0.000 description 2
- 108010016648 Immunophilins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 210000000413 sensory ganglia Anatomy 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102000009728 CDC2 Protein Kinase Human genes 0.000 description 1
- 108010034798 CDC2 Protein Kinase Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
- 101000596016 Homo sapiens TLR adapter interacting with SLC15A4 on the lysosome Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001328813 Methles Species 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100035166 TLR adapter interacting with SLC15A4 on the lysosome Human genes 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT a a Name of Applicant: Actual Inventor: Address for Service: Invention Title: VERTEX PHARMACEUTIC
INCORPORATED
David M. ARMISTEAD CULLEN CO., Patent Trade Mark Attorneys, 239 George Street, Brisbane, Qld. 4000, Australia.
METHODS AND COMPOSITIONS STIMULATING NEURITE GROWTH
ALS
FOR
The following statement is a full description of this invention, including the best method of performing it known to us: -la- METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH TECHNICAL FIELD OF THE INVENTION The present invention relates to methods and pharmaceutical compositions for stimulating the growth of neurites in nerve cells. The compositions comprise a neurotrophic amount of a compound which binds to the FK- 506 binding protein (FKBP) and a neurotrophic factor, such as nerve growth factor NGF. The methods comprise treating nerve cells with the above-described compositions or compositions comprising the FKBP binding compound without a neurotrophic factor. The methods of S. this invention can be used to promote repair of neuronal damage caused by disease or physical trauma.
15 BACKGROUND OF THE INVENTION Immunophilins are a family of soluble proteins that mediate the actions of immunosuppressant drugs such as cyclosporin A, FK506 and rapamycin. Of particular interest is the 12 kDa immunophilin, FK-506 binding 20 protein (FKBP12). FKBP12 binds En-506 and rapamycin, leading to an inhibition of T-cell activation and proliferation. Interestingly, the mechanism of action of FK-506 and rapamycin are different. For review, see, S.
H. Solomon et al., Nature Med., 1, pp. 32-37 (1995).
FK-506 binds to FKBP12 and the resulting complex binds to and inhibits calcineurin, a cytoplasmic phosphatase. The phosphatase activity of calcineurin is necessary for dephosphorylation and subsequent translocation into the nucleus of the transcription factor NF-AT. NF-AT causes interleukin-2 gene activation which in turn mediates T-cell proliferation.
The rapamycin-FKBP12 complex, on the other -2hand, associates with a protein of unknown function, termed RAFT1/FRAP. This tripartite complex is known to inhibit various kinases in the cell p70S6, p34cdc2, cdk2) which are necessary for cell cycle progression in T-cells. Rapamycin is also known to be a potent antagonist of FK-506, presumably by acting as a competitive inhibitor for the FKBP12 binding.
More recently, it has been discovered that FKBP plays other important roles in the body. It has been found that FKBP12 forms a complex with the intracellular calcium ion channels the ryanodine receptor (RyR) and the inositol 1,4,5-triphosphate receptor (IP 3 R) [T.
Jayaraman et al., J. Biol. Chem., 267, pp. 9474-77 (1992); A. M. Cameron et al., Proc. Natl. Acad. Sci. USA, 15 92, pp. 1784-44 (1995)], helping to stabilize calcium release. The ryanodine receptor has been found in skeletal muscle, cardiac muscle, brain and other excitable tissues. IP 3 R mediates intracellular calcium release elicited by hormones and neurotransmitters that act at the cell surface to activate phospholipase C and generate inositol 1,4,5-triphophase
(IP
3 Most IP 3 R is found associated with the endoplasmic reticulum, but some .may occur on the cell surface and mediate calcium flux into the cell.
25 For both the RyR and the IP 3 R, it has been demonstrated that FK506 and rapamycin are capable of dissociating FKBP12 from the receptor. In each case, the "stripping" off of FKBP12 leads to increased leakiness of the calcium channel and lower intracellular calcium concentrations.
Another role of FKBP12 is the regulation of neurite outgrowth in nerve cells. W. E. Lyons et al.
[Proc. Natl. Acad. Sci. USA, 91, pp. 3191-95 (1994)] demonstrated that FK506 acts synergistically with nerve growth factor (NGF) in stimulating neurite outgrowth in a rat pheochromocytoma cell line. Interestingly, rapamycin did not inhibit the effects of FK-506 on neurite outgrowth, but rather was neurotrophic itself, displaying an additive effect with FK-506. In sensory ganglia, FK- 506 demonstrated similar neurotrophic effects, but those effects were blocked by rapamycin. These results led the authors to speculate that FK-506 was exerting its neurotrophic effect through its complexing with FKBP12 and calcineurin and inhibition of the latter's phosphatase activity. Alternatively, the authors proposed FK-506 was acting via a "stripping" mechanism, such as that involved in the removal of FKBP12 from RyR iand IP 3
R.
In view of the wide variety of disorders that S 15 may be treated by stimulating neurite outgrowth and the relatively few FKBPl2-binding compounds that are known to possess this property, there remains a great need for additional neurotrophic, FKBP12-binding compounds.
***SUMMARY OF THE INVENTION 20 Applicant has solved the problem referred to above by discovering that two genera of novel FKBP12binding compounds he had previously co-invented also possess neurotrophic activity. Applicant had previously described a series of acylated amino acid derivatives which bind to FKBP12 in PCT patent publications WO 92/19593 and WO 94/07858. Another series of FKBP12 ligands are described in applicant's United States Patents 5,192,773 and 5,330,993 and PCT patent publication WO 92/00278. Each series of compounds stimulate neurite outgrowth in the presence of exogenous or endogenous NGF.
The compositions provided comprise a compound from one of the two genera described above and a neuronal -4growth factor. The methods described herein employ those previously described compounds and compositions comprising them to effectuate neurite outgrowth are useful to treat nerve damage caused by various diseases and physical traumas.
DETAILED DESCRIPTION OF THE INVENTION According to one embodiment, the present invention provides pharmaceutical compositions which comprise: a) a compound with affinity for FKBP12 having f the formula
K
D
Sowherein A in O, NH, or N-(C1-C4 alkyl); wherein B is hydrogen, CHL-Ar, (C1-C6) -straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (C1-C6)-alkyl or (C2-C6)-alkenyl, or and pharmaceutically acceptable derivatives thereof, substituted (Ci-C6)-alkyl or (C2-C6)-alkenyl, or
T
aL wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)straight or branched alkenyl; wherein T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4.i: alkenyl and carbonyl; wherein Ar is selected from the group consisting of l-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having one to three substituents which are independently selected from the group consisting 15 of hydrogen, halo, hydroxyl, nitro, CF 3 (C1-C6)-straight or branched alkyl or (C2-C6)straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-((C2-C4)-straight or branched alkenyl), O-benzyl, O-phenyl, amino and phenyl; wherein D is U; E is either oxygen or CH-U, provided :that if D is hydrogen, then E is CH-U or if E is oxygen then D is not hydrogen; wherein each U is independently selected from hydrogen, O-(C1-C4)-straight or branched alkyl or O- ((C2-C4)-straight or branched alkenyl), (C1-C6)straight or branched alkyl or (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; -6wherein J is hydrogen or C1 or C2 alkyl; K is (Cl- C4)-straight or branched alkyl, benzyl or cyclohexylmethyl; or wherein J and K may be taken together to form a 5-7 membered heterocyclic ring which may contain an O, S, SO or SO, substituent therein; wherein the stereochemistry at carbon position 1 is R or S; b) a neurotrophic factor; and c) a pharmaceutically suitable carrier.
More preferably, in the compound with affinity for FKBP12 in these pharmaceutical compositions: A is oxygen; J is hydrogen or C1 or C2 alkyl; K is (Cl- C4)-straight or branched alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form pyrrolidyl or piperidyl; and the stereochemistry at carbon position 1 is S.
In the above preferred compounds wherein J and K are taken together to form pyrrolidyl or piperidyl and E is CH-U, U is preferably dimethylaminophenyl, 20 methoxyphenyl, dimethoxyphenyl, trimethoxyphenyl, nitrophenyl, furyl, indolyl, pyridyl, or methylenedioxyphenyl.
In the above preferred compounds wherein J and K are taken together to form pyrrolidyl or piperidyl and S 25 E is oxygen: B is preferably benzyl, naphthyl, tert-butyl, hydrogen, E-3-phenyl-2-methyl-prop-2-enyl, E-3-(4-hydroxyphenyl) 2methyl-prop-2-enyl, E-3- [trans(4-hydroxycyclohexyl) methyl-prop-2-enyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclopentylopropyl, E-3-(4-methoxyphenyl)-2-methyl-prop-2-enyl, E-3-(3,4-dimethoxyphenyl)-2-methyl-prop-2-enyl or E-3- [cis(4-hydroxycyclohexyl) -2-methyl-prop-2-enyl; and D is preferably phenyl, methoxyphenyl, cyclohexyl, ethyl, methoxy, nitrobenzyl, thiophenyl, indolyl, furyl, pyridyl, pyridyl-N-oxide, nitrophenyl, fluorophenyl, trimethoxyphenyl or dimethoxyphenyl.
The most preferred compounds of formula (I) useful in the compositions and methods of this invention are those of formulae la, Ib, Ic and Id, listed in Tables la through Id, respectively, set forth in Example 1, below.
The synthesis of compounds of formula with affinity for FKBP12 in these compositions is described in United States Patents 5,192,773 and 5,330,993 and PCT patent publication WO 92/00278, the disclosures of which are herein incorporated by reference.
According to an alternate embodiment, the present invention provides pharmaceutical compositions 15 which comprise: a) a compound with affinity for FKBP12 having the formula (II): K' B' wherein B and W are independently: branched alkyl, (C2-C1o)-straight or branched alkenyl or
(II)
and pharmaceutically acceptable derivatives thereof, wherein A' is CH 2 oxygen, NH or N-(C1-C4 alkyl); wherein B' and W are independently: hydrogen, Ar', (C1-C10)-straight or branched alkyl, (C2-C10)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkyl substituted (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkenyl substituted -8- (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, or Ar' substituted (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl wherein, in each case, any one of the CH 2 groups of said alkyl, alkenyl or alkynyl chains may be optionally replaced by a heteroatom selected from the group consisting of O, S, SO, SO 2
N,
and NR, wherein R is selected from the group consisting of hydrogen, (C1-C4)-straight or branched alkyl, (C2-C4)straight or branched alkenyl or alkynyl, and (C1-C4) bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said heteroatom-containing chain to form a ring, and wherein said ring is optionally fused to an Ar' group; or (ii) *wherein Q' is hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl or alkynyl; wherein T' is Ar' or substituted 5-7 membered cycloalkyl with substituents at positions 3 and 4 which are independently selected from the group consisting of oxo, hydrogen, hydroxyl, O-(C1-C4)-alkyl, and 0-(C2-C4)-alkenyl; wherein Ar' is a carbocyclic aromatic group selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, and anthracenyl; or a heterocyclic aromatic group selected from the group consisting of 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3 -pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3triazolyl, 1, 3, 4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3, 5-triazinyl, 1,3,5trithiany., indoJlizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo fbifuranyl, benzo fbi thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4Hquinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1, 8-naphthyridinyl,.pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl; 0 wherein Ar' may contain one to three substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, hydroxymethyl, nitro, tri fluoromethyl, trifluoromethoxy, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, 0- 0 C-4 srih rbace ly] (C2-C4) -straight or branched alkeyl, 0-benzyl, 0-phenyl, 1, 2-methylenedioxy, amino, carboxyl, N-[(C-C5)-straight or branched alkyl or (C2-C5)-straight or branched alkenyl)carboxamides, N,N-di-( (Cl-CS) -straight or branched alkyl or (C2-C5) -straight or branched alkenyl))Icarboxamides, N-morpholinocarboxamide, N-benzylcarboxamide, N-thiomorpholinocarboxamjde, N-picolinoylcarboxamide, 0-X, CH 2
-(CH
2 ),qXi
O-(CH
2 )q-Xi (CH 2 )q0OXi and CH=CH-X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3, 5 -dime thyl isoxazoyl, isoxazoyl, 2-methyithiazoyl,.thiazoyl, 2-thienyl, 3-thienyl, or pyrimidyl; and q is 0-2; wherein G is U'; M is either oxygen or CH-U'; provided that if G is hydrogen, then M is CH-U' or if M is oxygen, then G is U'; wherein U' is hydrogen, O-H(Cl-C4)-straight or branched alkyl] or O-[(C2-C4)-straight or branched alkenyl], (C1-C6-straight or branched alkyl or (C2-C6) -straight or branched alkenyl, (C5-C7) -cycloalkyl or (C5-C7) -cycloalkenyl substituted with (Cl-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, Soo* 15 [(C1-C4-alkyl or (C2-C4)-aknl- rY -C4 S.knyl rY Swherein Y is selected from the group 6 consisting of phenyl, 1-naphthyl, 2-naphthyl, Goes indenyl, azulenyl, fluorenyl, anthracenyl, 2pyrrolinyl, 3-pyrrolinyl, pyrolidinyl, 1,3-
OGG*
0000 20 dioxolyl, 2-imidazolinyl, imidazolidinyl., 2H- 9SO.
G pyranyl, 4H-pyranyl, piperidyl, 1, 4-dioxanyl, morpholinyl, 1, 4-dithianyl, thiomorpholinyl, :,Gore piperazinyl, quinuclidinyl, and-heterocyclic e.aromatic groups as defined for Ar' above; wherein Y may contain one to three V664 suibstituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, (Cl-C6)-straight or branched alkyl, (C2-C6) -straight or branched alkenyl, O-((C-C4-straight or branched alkyl], 0- C2-C4)-straight or branched alkenyl], 0-benzyl, 0-phenyl, l 1 2-methylenedioxy, amino, and carboxyl; -11wherein J' is hydrogen, (C1-C2) alkyl or benzyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylmethyl, or wherein J' and K may be taken together to form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO 2 and wherein m is 0-3; b) a neurotrophic factor; and c) a pharmaceutically suitable carrier. The compounds of formula (II) exclude any compounds of formula More preferably, in the compound with affinity for FKBP12 in these pharmaceutical compositions: and W are independently: 15 hydrogen, Ar', (C1-C10)-straight or branched alkyl, (C2-C10)-straight or branched alkenyl or **alkynyl, (C5-C7)-cycloalkyl substituted (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkenyl substituted 20 (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, or Ar' substituted (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl wherein, in each case, any one of the CH 2 groups of said alkyl, alkenyl or alkynyl chains may be optionally replaced by a heteroatom selected from the group consisting of O, S, SO, SO2; or (ii) Ar' may contain one to three substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or -12branched alkyl, (C2-C6)-straight or branched alkenyl, O-[(C1-C4)-straight or branched alkyl], O-[(C2-C4)-straight or branched alkenyl], O-benzyl, O-phenyl, 1,2-methylenedioxy, amino and carboxyl; and Y is selected from the group consisting of phenyl, l-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl and heterocyclic aromatic groups as defined for Ar' above.
According to other preferred embodiments, in the compound with affinity for FKBP12 having the formula
(II):
at least one of B' or W is independently selected from the group consisting of (C2-C10)-straight or branched alkynyl; (C5-C7)-cycloalkyl substituted (C2-C6)-straight 15 or branched alkynyl; (C5-C7)-cycloalkenyl substituted (C2-C6)-straight or branched alkynyl; and Ar' substituted (C2-C6)-straight or branched alkynyl.
Alternatively, at least one of B' or W is independently represented by the formula -(CH 2
(CH
2 wherein: Z is independently selected from the group consisting of
CH
2 O, S, SO, SO 2 N, and NR; r is 0-4; s is 0-1; and Ar' and R are as defined above in formula II.
In yet another alternative embodiment of formula II, at least one of B' or W is independently selected from the group consisting of Ar', Ar'substituted (C1-C6)-straight or branched alkyl, and Ar'substituted
(C
2 -C6)-straight or branched alkenyl or alkynyl; wherein Ar' is substituted with one to three substituents which are independently selected from the group consisting of N-(straight or branched (C1-C5)-alkyl or (C2-C5)-alkenyl) carboxamides, N,N-di-(straight or -13branched (C1-CS)-alkyl or N-morpholinocarboxamide, N-benzylcarboxamide, N-thiomorpholinocarboxamide, N-picolinoylcarboxamide, O-X, CH 2
-(CH
2
O-(CH
2
(CH
2 and CH=CH-X; and Ar', X and q are as defined above.
Most preferably, the compounds of formula (II) used in the pharmaceutical compositions are selected from those of formula listed in Table 2, set forth in Example 1.
The synthesis of compounds of formula II is described in detail in applicant's PCT patent publications WO 92/19593 and WO 94/07858, the disclosures of which are herein incorporated by reference.
As used herein, the FKBP12 binding compounds 15 used in the pharmaceutical compositions and methods of this invention, are defined to include pharmaceutically acceptable derivatives thereof. A "pharmaceutically acceptable derivative" denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of a compound of this invention or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to promote or augment neurite outgrowth.
If pharmaceutically acceptable salts of the FKBP12 binding compounds are used, those salts are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, -14methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-Dglucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogencontaining groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, 15 long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water S* or oil-soluble or dispersible products are thereby obtained.
20 The FKBP12 binding compounds utilized in. the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system blood, lymphatic system, central r. nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
The neurotrophic activity of the FKBP12 binding compounds of this invention is directly related to their affinity for FKBP12 and their ability to inhibit FKBP12 rotomase activity. In order to quantitate these properties, several assays known in the art may be employed. For example, competitive LH20 binding assays using labelled FK-506 as a reporting ligand have been described by M. W. Harding et al., Nature, 341, pp. 758- (1989) and by J. J. Siekierka et al., Nature, 341, pp.
755-57 (1989).
Preferably, the assay measures inhibition of FKBP12 rotomase activity. Such an assay has also been described by M. W. Harding et al., sumra and by J. J.
Siekierka et al., supra. In this assay the isomerization of an artificial substrate N-succinyl-Ala-Ala-Pro-Phep-nitroanilide is followed spectrophotometrically.
The assay includes the cis form of the substrate, FKBP12, the inhibitor and chymotrypsin. Chymotrypsin is able to cleave p-nitroanilide from the trans form of the substrate, but not the cis form. Release of p- 15 nitroanilide is measured.
The second component in each of the pharmaceutical compositions described above is a neurotrophic factor. The term "neurotrophic factor", as used herein, refers to compounds which are capable of stimulating growth or proliferation of nervous tissue.
As used in this application, the term "neurotrophic factor" excludes the FKBP12 binding compounds described herein, as well as FK-506 and rapamycin.
Numerous neurotrophic factors have been identified in the art and any of those factors may be utilized in the compositions of this invention. These *..neurotrophic factors include, but are not limited to, nerve growth factor (NGF), insulin growth factor (IGF-1) and its active truncated derivatives such as gIGF-1, acidic and basic fibroblast growth factor (aFGF and bFGF, respectively), platelet-derived growth factors (PDGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3)and neurotrophin 4/5 The most preferred -16- .neurotrophic factor in the compositions of this invention is NGF.
The third component of the pharmaceutically acceptable compositions of this invention is a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium 15 chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium S. carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
Preferably, the compositions are administered orally, intraperitoneally or intravenously.
Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension.
These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile -17injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterallyacceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic monoor di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceuticallyacceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil 15 solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.
The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch.
Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable nonirritating excipient which is solid at room temperature -18but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.
Topically-transdermal patches may also be used.
15 For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited ~to, mineral oil, sorbitan monostearate, polysorbate cetyl esters wax, cetearyl alcohol, 2 -octyldodecanol, benzyl alcohol and water.
For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as -19benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
The amount of both FKPB12 binding compound and the neurotrophic factor that may be combined with the 15 carrier materials to produce a single dosage form will vary depending upon the host treated, the particular mode of administration. The two active ingredients of the pharmaceutical compositions of this invention act synergistically to stimulate neurite outgrowth.
Therefore, the amount of neurotrophic factor in such pcompositions will be less than that required in a monotherapy utilizing only that factor. Preferably, the compositions should be formulated so that a dosage of between 0.01 100 mg/kg body weight/day of the FKBP12 binding protein can be administered and a dosage of between 0.01 100 ug/kg body weight/day of the neurotrophic can be administered to a patient receiving these compositions.
It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredients will also depend upon the particular FKBP12 binding compound and neurotrophic factor in the composition.
According to another embodiment, this invention provides methods for stimulating neurite outgrowth. Such methods comprise the step of treating nerve cells with any of the FKBP12 binding compounds described above.
Preferably, this method is used to stimulate neurite outgrowth in a patient and the FKBP12 binding compound is formulated into a composition additionally comprising a pharmaceutically acceptable carrier. The amount of FKBP12 binding compound utilized in these methods is between about 0.01 and 100 mg/kg body weight/day.
15 According to an alternate embodiment, the method of stimulating neurite outgrowth comprises the additional step of treating nerve cells with a neurotrophic factor, such as those contained in the pharmaceutical compositions of this invention. This embodiment includes administering the FKBP12 binding compound and the neurotrophic agent in a single dosage form or in separate, multiple dosage forms. If separate dosage forms are utilized, they may be administered concurrently, consecutively or within less than about hours of one another.
Preferably, the methods of this invention is used to stimulate neurite outgrowth in a patient.
The methods and compositions of this invention may be used to treat nerve damage caused by a wide variety of diseases or physical traumas. These include, but are not limited to, Alzheimer's disease, Parkinson's disease, ALS, stroke and ischemia associated with stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, sciatic crush, spinal cord injuries and facial nerve crush.
-21- In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
EXAMPLE 1 FKBP12 Binding Assay The inhibition of FKBP rotomase activity by the preferred FKBP12 binding compounds present in the compositions of this invention was assayed. In this assay various quantities of FKBP12 binding compound (0.1 nM 10 uM) were added to cis-N-succinyl-Ala-Ala-Pro-Phep-nitroanilide in the presence of FKBP12 and chymotrypsin. FKBP12 converts the cis form of the 15 substrate to the trans form. This allows chymotrypsin to cleave p-nitroanilide from the substrate. Release of pnitroanilide was measured spectrophotometrically. This assay allowed me to measure the change in the first order rate constant of the rotomase activity as a function of 20 FKBP12 binding compound concentration and yielded an estimate of apparent Ki. The most preferred FKBP12 binding compounds utilized in the compositions and 0* methods of this invention and their calculated K i are tabulated below.
-22- TABIL-1A
S
S. 55
S
S
S
*5*S (formula Ia) B D n KVftM) Benzy4 Phenyl 1 Benzy Phenyl 2 AmPhenyl 2 8 1-Naphthyl Phenyl 2 0.9 2- Naphthyl Phenyt 2 7 Benzyl 2-Methytpropyl 2 0.9 10 Benzyl 2-Methoxyphenyl 2 17 Benj 3-Methoxyphenyl 2 0.3 Benzyl 4-Methoxyphenyl 2 Benzyl '3,5-Dimethoxyphenyt 2 2 Benzyl 2 6-Dimethoxyphenyt 2 15 Benzyt 3.4.5-Tdmethoxyphenyl 2 0.1 Benzyl 4-Fluarophenyt 2 4 Benzy 3-NitropheNy 2 160 Benzyl 4-Nitrophenyl 2 160 Benzyt 2-Pywdyl 2 130 20 Benzyl 2-pyndylN-oade 2 >500 tert-Butyl 2-Fuyt 1 200 Benzyi 2-Furyl 2 3 Benzyl 3-Indoyl 2 Benzyl 2-Thiophanyl 2 0.8 E-3-Phenyl-2-meth 4prop) 2-enyI Phenyl -2 E-3..(4-Hydroxyphenyl)-2-methylprop-2- Phenyl 2 6 E-3-fcr(4-Hydroxycohey)-2-meit* Phenyl 2 0.6 E-3-(trans(4-HydoxycyclOheyl)J.2- Phenyl 2 2-Nitrobenzyl 2 26 Hydrogen________ Methoxy 2 ND 1 600 352 190Ieto -23a. a a a. a.
a V. a
V
a B 0n (lzM) Benzyl Methoxy 2 2-Cydlohexylethyl Methory 2 3-Cyclohe ylropy Methoxy 2 4-Cyciohexylbutyl Methoxy 2 6 3-Cyclopentylpropyl Methoxy 2 E-3-(4-Mhoxyphenl)2-methy-prop-2- Methoxy 2 E-3-(3,4-Dimethoxyphenyl)-2.methyl. Methoxy 2 E-3-(4-Hydroxyphenyl)-2-methyl-prop-2- Methoxy 2 E-3Ici4-Hydroxyohexyl)-mthyl. Methoxy 2 prop-2-eny Benzyl CycloheWy 2 1.3 Benzyl Ethyl 1 400 ienry 3-Mehomypenyl 1 Benzyl 2-Pydy 1 300 Benzyl 3,4-Difluorophenyl 2 Benzyi -2-(4-Methoxyphenyl)-ethenvI 2 1 Benzyl i-Hydroxy-l-cycloheWy 2 1 Benzyl 2-Naphthvl 2 Benzyi 1-Naphthyl 2 1 (S)-alpha-Methytbenzyl Phenyl 2 Benzyl 2-Hydroxv-2-tetrahydropyranyl 2 12 (R)-alpha-Methylbenzyl Phenyl 2 Benzyl 3-Trffluoromethylphenyl 2 Benzyl 3-Benzyloxyphenoy 2 eizyl (E)-2-tert-Butylethenyl 2 9 Benzyl 2-Trifluoromethytphenyl 2 4-ycloheylbuty1 Phenyl 2 0.4 4-Cy lhexylbutyl 3,4,5-Tfimethqxyhenyl 2 0.04 4-phenylbenzyt Phenyl 2 4-Phenyibenzyl 3 4 5-Tfimethoxyphenyl 2 2 Benzyl 3-Ethoxyphenyl 2 0.56 3-Phenoxybenzyl 3,4,5-Tdmethoxyphenyl 2 0.018 3-Phenoxybenzyl Phenyi 2 0.09 4-Phenylbutyl 3 4 5-Tnmethoxyphenyl 2 0.019 4-Phenviuv Phenyl 2 0.35 Beny 3 -43-Pmipenlxy)phenyl 2 1 Benzyl 342-Propoxy)phenyl 2 Beny 1-Methyipropyl 2 1 2-Phenylethyl Phenvi 2 1.1 6-Phenythexy PheyA 2 '3,4,5-TdMethoxyhenyl 2 0.07 6-Phenythexy 3 4 5-Tdmethoxyphenyl 2 0.1 ",Aycl h wAhxy 3 ,5-Tnmethoxyphenyl 2 0.05 14-Phenoxybenyl A 3.5-Tnmethoxyphenyl 2 0.8 3.4.5-Tfimethoxvoherwl 2 0.09 -24- B D n IKftPM) 3-(l-Butoxy)pheny 2 0.36 4- Phenylbutyl 34(2-Propoxy)phenyl 2 0.1 j4-ldo hen bV 3.4.5-Tdmethoxyphenyl 2 0.016 4-odobenzyf 3 4 5-Tdmethoxyphenyl 2 1.4 2-(2-Naphthy~tyl 3,4,5-Tnimethoxyphenyl 2 0.22 2-(1-Naphthyl)ethyl 3 4 5-Tdmethoyphenyl 2 4-Phenyfbuty 4-lodophenyl 2 0.8 4-Phenylbutyl 3-lodophenyl 2 0.13 3-Phenypropyl- 3.4,5-Tvimethoxyphenvl 2 0.11 3-{3-IndoMy)Propyl 3.,5Tmethoxyphenyl 2 0.017 4-4-Metho phen lbuy 3,4.5-Trimethoxyphenyl 2 0.013 4-Phenylbut-2-enyi 3 ,5-Tiimethoxypheng 2 0.8 4-Phenylbut-3-enyl 3,4,5-Trimeth xyhenyl 2 4-Ailocaminopheny roN 3 4 -Tmethoxyphenyl 2 0.011 4-Phenylpropyl- 1-Cyclohexenyl 2 0.78 4-(4-Methoxvphenyf)but-3.enyt 3.4.5-Trimethoxyphenyl 2 1 0.011 4-phenylpropy I-Fluoro-i-cyclahe*y 2 0.54 4-Phenyoropyl 3-Butoxypheny 2 1.4 343-4N-Formyindo)propyl 3.4.5-Tnimethqxyphenyl 20.015 !434ndoM)butyl 3 L4 ,5-Trimethoxyphenyt .2 0.016 4-Phenylbutyl Benzyl 2 0.35 4-Phenylbuy 3-Biphenyl 2 0.04 4-Phenylbutyl 4-tert-Butyphenyl 2 0.6 4-Phenytbutyl Cyctohexyl 2 0.08 4-PhenylbutVI Cyctahexylmethyl 2 0.12 4-Pheyluyl 34-Methylenedioxyphenyi 2 0.25 4-Pheny buy 4-Tetrahydropyranyl .2 0.44 4-Phenytbutyl 3-Cyclohexyl-4-methoxv- phenyt 2 14 4-Phenylbutyl 4-{4-Methoxybenzyoxy-methy).2. 2 0.7 fury 4-Phenybutt tert-Butyi -2 0.18 4-Phen lbu Ethyl 2 1.6 3-4N-BenziftdazoMy)propyl 34,5-Trimethoxyphenyl -2 0.11 3-(N-Punnyl)propyt 3 '4 '5-Trimethoxyphenyt 2 0.13 (SS -2-Meth l-3-hydroxV-4- pheN~ po 3,4.5-Tfimethoxyphenyl 2 0.25
C.
C. C
C.
C
C.
C
C
TASL 1 b
S
59 (formula lb) B U n K BenzyL. 3,4-Methylenedioxyphenyt 1 3 Bezy 3,4-Methyenedioxyphenyl 2 3 Bezy 4-Methoxyphenvl 1 6 Benzyl 14-Methoxypherryl 2 4 Benzyl 2,5-.Dimethoxyphenyl 1 Benyl... 2,4,5-Tnmethoxyphenyl 1 Benzyl 3,4,5-Thmethoxyphenyl 1 450 BenzlI 4-Dimethylaminaphen1 2 Berzt~ 4-Nttropheiyl 2 14 Bewnz~l I-Fuyl 2 Benzyl 2-Furyl 2 IBerzvi 3-Indoyl 21 Be 3-Pyndyl 2 Ben Hydrogen 2 300 BeL. Pheny 2 11 .9 59 9 9 9S*6
S
55.5 -26- TARTF. 1 r (formula Ic) B D J K K him) Benzyt Methoxy Mefiyj Hydrogen 1000 s§my Methoxy Methl S-Isoprowl, 170 Ee IMethoxy 18en 1HYdrogen '1200 Itert-Bu, IMethoxy JEy IS-Me"hy :400 0 **s Stoo *00
IALWI
0S5@ 6 S 6005 (formula Id) B U J K #j) Bezy 4-methox enyl Mehl SMty 801 Bey 3 4 -Methylenedioxyphenyl Methiyl S-ey s0 Beny 13.4-Methylenedioxvheny I"jdragen IS-Methyl J -27- TARTY 2 (formula III) 0.0.
00.
0 e*t.
C p d. n m B'W Ar' K (W) 2 1 03-(Pyddin-2-yl) propyl I-Penypropyl 3,4,S-Tnmethoxyheny 3 2 10 13-Phenylpropyl 3.-Phenylpropyl 3,.5-Trimethoxyphenyl 1.
4 2 0 3-Phenoxyphenyt 3-Phenyipropl 3,4,5-Thmolhoxyphenyt 220.
2 0 Phenyl 3-Phenoxyphenyl 3,4,5-Trimethoxyphenyt 4.000.
6 2 0 Phenyl 3.Phenylpropyl 3,4.5-Trimethoxyphenyl 7 2 0 2-(Pyridin-3.yl) ethyl 3-Phenylpropyl 3,4,5-Tfmethoxyphenyl 3.
8 2 0 E.3-{trans-(4- 3.-Phenyipropyl 3,4,5-Tnimethoxyphenyi 27.
Hydroxycyclo-hexy)J-2- I methyl-eth-2-enyl -9 2 10 13-(Pyridin-3-yl)propyl 3-Phenyipropyl 3,4,5-Tdmethoxyphenyl 2 10 B8enzyl 3-Phenyipropyl 3,4,5-Tdmethoxyphenyl 32.- 11 2 0 Benzyl 3-OIndol-3-yl) propyl 3,4.5-Tdmethoxyphenyl 24.
12 2 0 2-Phenylethyl 3-Phenylpropyl 3,4,5-Tfimethoxyphenyl 83.
13 2 0 2-(4-MethoxV-phenyl)ethy 3-Phenylpropyl 3,4,5-Tnmethoxyphenyt 14 2 0 2-(4-Methoxy-phenyl)ethyl 3-Phenyipropyl Phenyl 270.
2. 0 34(N-Benzimidazoyl)propyl 3-Phenyipropyl 3,4.5-Tvimethoxyphenyl 16 2 1 Benzyl 2-Phenylethyl 3,4,5-Tdimethoxyphenyl 57.
17 2 0 3-(4-Methoxy- 3-Phenypropyl 3.4,5-Tdmethoxyphenyl 3.
phenyl)propyl 18 2 0 3-(Pyridin-3-yi)-propyi 3-Phenypropyl Phenyl 56.
19 2 0 3-(Pyridin-2-yl)-propyl 3-Phenylpropyl Phenyl s0.
2 0 34Pyridin-2.yi)-propyl 3-Phenypropyl 13,4.5-Trimethoxyphenyl 21 2 0 3-(Pyidin-2-fi)-propyl 3-Phenypropyl tert-Butyl i 36.
22 2 0 3-(Pyrtdin-3-yI).ptopy1-N- 3-Phenypropyl 3,4,5-Tdmethoxyphenyt 7.
23 2 0 3-N(7-AzaindoMy)-propyt 3-Phenyipropyl 3,4.5-Tfimethoxyphenyl 9 24 2 10 13-{Pyridin-3-yi)-propyl 3-{4-Methoxy-phenyl) 3,4,5-Tuimethoxyphenyt ND 2 10 13-(N-Purny) propyl 3-Phenylpropyl 3,4.5-Tnmethoxyphenyi 2.2 26 2 10 13-(4-Hydroxy- 3-Phenylpropyl 3,4.5-Tulmethoxyphenyl 4.
methylphenyl) propyi 27 2 10 13-Pyridin-3-yi)-propi 3-Phenylpropyl 3-Benzyloxypheny 28 2 10 13-(Pytdin-3.0propyl 3-Phenylpropyl 34Ulyoxyphenyl1.
292 10 13-(Pidin-3,A)-propyI 3-Phenylpropyl 13-sopropoxyphenyl 2.
2 10 13-(Thophen-2-yi)-proNv 3-PheNypropyl J3,4,5-TriMethOxyphenv1 4.
-28- Cpd. n im B' W Ar' (nM) 31 2 0 13-4CarboxyphenyI)propyl 3-Phenylpropyl 3,4,5-Tdmethoxypheny 2.
32 2 0 13-Phenybutyl 3-Phenylpropyl 3,4,5-Tdmethoxyphenyt 33 2 0 12-Hydroxymethylphenyl 3-Phenylpropyl 3,4,6-Trimethoxyphenyt 89.
34 2 0 12-Alyoxyphenyl !3-Phenyipropy !3,4,5-Tfimethoxyphenyl 150.
2. 0 1343-Hydroxymethyiphenyl) 3-Phenylpropyt 3.4,5-Thimethoxyphenyt 1.
36 2 10 13-(3-Carboxyphenyl)propyl 3-Phenylpropyl 3,4,5-Tdmethaxypheny 7.
37 2 10 13-Hydroxymethylphenyt 3-Phenypropyl 3,4,5-Trimethoxyphenyl 6.8 38 2 10 12-Hydroxyphenyl 3-Phenypropyl 3.4.5-Trimethoxypheny ND- 39 2 10 jPyrtdin-3-yi 3-Phenylpropyl 3,4,5-Trimethoxyphenyt
ND
2 0 13-(Thiopen-2-yl)-propyl 4Phenytbutyl 3,4,5-Tdmethoxyphenyl 1,100.
41 2 0 15-Phenytpentl 3-Phenypropyl 3,4.5-Trimethoxyphenyl 42 2 0 13.Axypropyl 3-Phenyipropyl 3,4,5-Timethoxyphenyl
ND
43 2 0 13-4-(NN-Dimethylamine- 3Phenylpropyl 3,4,5- etioxypheny .carbonyl)-pheiyi propyl 44 2 10 1344-(Morpholine-4. 3-Phenylpropyl 3.,5-Tdmethoxyphenyl 6 carbonyl)phenl}propyi 2 10 14-Allyxybutyl 3-Phenylpropyl 3.4,5-Tnimethoxypheny 7.
46 2 10 13-MJy~xy-prop-1-ynyi 3-Phenylpropyl 3.4,5-Timethoxyphenyl 47 2 10 13-4(Piperndine-1- 3-Phenylpropyl 3.4.5-Trimethoxyphenyi 7.
carbonyl)phenyqpropyl 48 2 10 15-Allyoxynonyt 3-Phenyipropyl 3,4,5-Trimethoxypheny4
ND
49 2 0 jMethyl 3,5- 3,4,5-Tfimethoxyphenyl 3.400.
2 0 12-Allyoxyethyi 3-Phenylpropyl 3.4,5-Trimethoxyphenyl 11.
51 2 0 13-Altyoxy-(E)-prop-1-yny 3-Phenypropyl 3.4,5-Trimethoxyphenyl 2.8 52 2 0 13-13-(Morpholine-4- 3-Phenylpropyt 3.4,5-Trimethoxyphenyl carbonyl) phenyllpropyl 53 2 0 lDec-9-enyl 3-Phenyipropy 3,4,5-Tflmethoxyphenyl ND 54 2 0 13*4(N-Benzyl- 3-Phenylpropyl -3.4,5-TrimethoxypheNy 1.6, aminecarbony -pheNlpropyl 2 0 13-(4-(Thiomorphoilne-4- 3-Phenylpropyl 3.4.5-Tfimethoxyphenyi 2.4 carbonyl)lphenylpropy 56 2 10 13-(Morphofine-4- 3-Phenyipropyl 3 .4,5-Tnimethoxyphenyl 6.1 carbonyl)phenyi- 57 2 10 13441-Methy-piperazne- 3-heytpropyl 3.4.5-Trimethoxyphenyl 5.6 4-cabonyi)phenylJ propyl 58 21 0 13-(1(-Benzyl-piperazine- 3-Phenyipropyl 3.4,5-Trimethoxcyphenyl 4-carboni)phenAi propyt 59 2 10 13-3-(N-Benzyl-amine- 3-Phenyipropyi 3.4,5-Thimethoxyphenyl carbanyi)phenypropyl 21 0 4N-Pywidin-2- 3-Phenyipropyl 3.4.5-Tiimethoxyphenyl 2.
ylaminecarbon- -phenylipropyl 61 2 10 IPryidin-3-yl 3-(Pyfidin-3-yl).propyl 3.,5-Tdmethoxyphenyi 62 2 0 lProp-2-onyl 3.4-Bis-(PYfiin4 3 ,4,6-Tiimetoxyphenyl 62.
63 2 0 Py~idin-3-yi 3-(Pyuidin-4-yt 3.4.5-Tnimfthoxheny 13.
rn1 ethoxy)phenyi_ 3-nlpropyl 3mjthnwunh4nu 3.4,5-Trimethoxyphenyt m t 'r -29-
SS**
Cpd. nm B. W Ar' K nM) 2 0 3-Phenylpropyl 3,4-Bis-(Pyridin-4- 3,4,5-Tfimethaxyphenyi 4.1 66 2 0 Methyl 3.4..Bis-(Pyrldin-4- 3.4,5-Trimethoxypienyi 67 2 0 3-Phenylpropyl 2,3,4-Tris-(Pyridin-4- 3,4,5-Tnmethoxyphenyi 46.
methox)phenyl 68 2 0 3.Phenylpropyl 3-(Morpholine-4- 3.4,5-Tdmethoxyphenyl 2.
carbonyl)-4-Pyridin-4ylmethoxy)phenyl 69 2 0 Methyl 3,4,5-TrisPyidin-4- 3.4,5-Trirethoxyphenyl 36.
ylmethoxy)phenyl 2 0 3-Phonylpropyl 3,4,5-Tris-(Pyridin-4- 3,4,5-Trimethoxyphenyl5 IIymethoxy)phenol____ 71 2 0 IMethyl 3,5-Bis-(Pyridin-4- 3.4,5.Tdmethoxyphenyl 14.
~ytmethoxy)phenyl____ 72 2 0 13,5-BiS-(Pyuidin-4- Methyl 3,4,5-Tnimethoxyphenyl 12.
ytmethoxy) phenyl_____ 73 2 0 IMethyl 3,5-Bis-(Pyridin-4. 3,4.5-Tiethoxyphenyl *36.
yfmethoxy)-4-Methyt- 74 2 10 lEthyl 3.4,5-Tris-(PyTidin-4- 3.4,5-Tdmethoxyphenyl 18.
2 10 13,4,5-Tfis(Pdin4-l. Ethyl 3.4,5-Ttimethoxyphenyl 12.
methoxy)phenyl -76 2 10 lProp-2-enyl 3,4,5-Tris-(Pyridin-4- 3,4,5-Tdmethoxypheny 14.
77 2 0 Methyl ~ylmethoxy)phanol 77210 ~to3.4,6-Trls-(Pyvidin-4- 3,4-Dimethoxyphenyi 24.
-78 2 10 lEthenyi 3,4,5-Tri.-Pyridin-4- 3.4.5-Trimethoxypheny 73.
~~~ylmethoxy)phenyl 79 2 10 13,4,5-Tris(Pyridin-4- Ethenyl 3,4,5-Trimethoxyphenyl 2.3 ylmethoxy)phenyt 80 2 10 lPrapyl 3.4.5-Tris-(Pyndin4- 3.4,5-Tnimethoxyphenyl 17.
81 2 1013,4,5-Tds-(Pyidin-4- Propyi 3,4,5-Trimethoxyphenyt -ylmethoxy)phenyi 82 2 10 IMethyl 3,4,5-Tris-(Thiophen- 3.4,5-Trimethoxyphenyl >5000 83 2 10 j3,4,5-Tris-Thio-phen-3- Methy 3,4,5-Tflmethoxyphenyl ylmethoxy)-phenyl_________ 84 21 0 IMethyl 2-lsopropoxy-3.4-Bis- 3.4,5-Trimethoxyphenyl 54.
(Pyridin-4-ylmethoxy)- 2 1012-isopropoxy-3,4-Bis- Methyl 3,4,5-Tdmethoxyphenyl (Pyuidin-4-ylmethoxy) 86 1 10 IMethyl 3.4,5-TriS-(Pylidin-4- 3.4,5-Thmethoxyphenyl 280.
methoxy)phenyl 87 1 0 .4,5-Tris-(Pyiidin-4- met"y 3.,5-Trlmethoxyphenyl 360.
ylmethox)phenyl 88 2 0 Methyl 3,4,5-Tris-(Pyvimidin- 3,4,5-Trimethoxyphenyl 19.
89 2 0 Benzyloxymethyt Benzyoxyphenyi 3,4,5-Trimethoxyphenyt 2 0 Methy 3,4,5-Tris- 3,4,5-Trmethoxyphenyi 2,600.
PO (Benzyloxy)phenyl S. S.
S
S
Cpd. 1n, m B'W Ar V-4(nM) 91 2 0 13-Phenylpropyl 3-(Pynidin y- 3,4,5-Timethoxyphenyl 24.
carbonyiphenyl 92 2, 0 j3-Pyridin-3y- 3-Phenylpropyl 3,4,5-Trimeffioxyheno1 9.
carbonylthenyi 93 2 10 13-Phenylpropyl 3-{Pyridlfl-4-yl- 3,4-imethoxyphenyi 94 2 10 13-Phenylpropyl 3-(Pydidin-4-yI- 4-Benzyloxy-3,5-Di- _____________carbonyl)phenyl methoxyphenyl 2 10 13-Phenylpropyl 3-(Pyfidin4* 4-loxy-3,5-Di- 3.6 bonyl)phenyl methoxyphenyl 96 2 0 3-Phenylpropyi 3-(Pyvidin-4y- 3-BenzyIoxy-4. -carbonyl~phenyi methoxyphenyl 97 2 0 3-Phenylpiopyl 3-(Pyrichn-4yI 3 -JoxY-4-methOxcYphenyt 17.
98 2 0 3-Phenylpropyl 3-(Pyridin-4.yl 34f3-Phenyl-(E)-prop-2- 380.
____________carbonft~henyl Onyl-4methoxyphenyl 99 2 0 13-Phenylpropyl 4-Pyridin-4.yt- 4-enzyloxy-350D- 15,000.
methoxyphenyr____ 100 2 0 13-Phenlprpyf 4-Pyridin-4*1 3-Senzyloxy-4- >500 ____________carbonyl)phenyl methoxyphenyl 101 2 0 13-Phenylpropyl 3-(Pyidin4* 3.4,5-Trimethoxyphenyl
ND
102 2 0 13-Phenytpropyl 3-(Pyidin-4yl 3,4-Dimethoxyphenyt
ND
103 2 0 13-Phenypropyl Phenyl 3-Benzyfoxy-4- 24,000.
methoxyphenyl 104 2 0 3-PhenylproWy Phenyl 4-Benzytoxy-3,5. 1,700.
___________Dunethoxyphenyl 105 1 0 3-(Pyrin-3-yl)-propy 3-Phenylpropl tert-Butyl 340.
106 2 0 3-PYidn-3-y)-popy1 3-(Pyiidin-3-yI)-propyl 3.4,5-Tuimethoxyphenyl 3.7 107 1 10 jBenzyfoxymethyl Benzyfoxymethyl 3,4,5-Trimethoxyphenyt 75,000.
01-( *idn3-yI)-propyl 3-(Pyrtdin-3-yl)-propy1 3,4,5-Trimethoxyphenyt 89.
109 2 0 13-(Pyridin-3-yI)-propy 3-(Pyridin-3-yl)-propyl Isopropyl 1,500.
110 2 0 j3-(Pyridin-3-yl)- 3-(Pywidin-3-yI)- Thiophen-2-yi
ND
111 2 0 13-(Pyridin-3-yI)-propyl 3-(Pyfidin-3-yI)-propy1 3.4-Methylenedioxy-phenyi
ND
112 2 01 3(ydin-3-y)-prop-2-ynyl 3-Pn-3-l)-prop- 3.4-Methylenedioxy phenyl ND 113 2 0 j3fldirn3-)prop2-qiyl 3-(PYfidin-3-yi)-prop. 3,4,5-Tfimethoxyphenyl
ND
114 2 0 13-(Pyrichn-2-yi)-propyl 3-Pdn2-y Q-rpf34,-dehxylnl
N
115 2 0 I1sopropyl 3.4,5-Tris.Pyrdin-4- 3.4,5-Trimethoxyphenyl 0.39 116 -methoxy)phenyl 16203,4,5-Tiis-(Pyvidin-4- Isopropy 3.4,5-Tdmethoxyphenyt 13.
ylmethoxy)phenyl 182 0 13,4,5-Tdis-(Pyridin-4- Prop-2-enyl 3,4,S-Tfimethoxyphenyl12 ylmethoxy)phenyl Assay of Neurite Outgrowth in PC1-2 Culture-s In order to directly determine the neurotrophic -31activity of the FKBP12 binding compounds utilized in this invention, the assay described by W. E. Lyons et al., Proc. Natl. Acad. Sci. USA, 91, pp. 3191-95 (1994) is carried out.
PC12 rat pheochromocytoma cells are maintained at 37 0 C and 5% C0 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated horse serum (HS) and 5% heat-inactivated fetal bovine serum (FBS).
The cells are then plated at 10 per 35mm culture well coated with 5 pg/cm 2 rat tail collagen and allowed to attach. The medium is then replaced with DMEM 2% HS and 1% FBS, NGF (1-100 ng/ml) and varying concentrations of-an FKBP12 binding compound (0.1 nM 10 pM). Control cultures are administered NGF without FKBP12 binding 15 compound.
The FKBP12 binding compounds utilized in this invention cause a significant increase in neurite outgrowth over control cultures.
20 Assay of Neurite Outgrowth in Dorsal Root Ganalion Culture Another way to directly determine the neurotrophic activity of the FKBP12 binding compounds utilized in this invention is the dorsal root ganglion 25 culture assay also described by W. E. Lyons et al., Proc.
Natl. Acad. Sci. USA, 91, pp. 3191-95 (1994).
In this assay, dorsal root ganglia are dissected from 16 day rat embryos and cultured in collagen-coated 35mm dishes with N2 medium at 37 0 C in a 15% C0 2 environment. Sensory ganglia are then treated with various concentrations of NGF (0 100 ng/ml) and an FKB12 binding compound (0.1 nM 10 pM). Ganglia are observed every two days under a phase contrast microscope and axon lengths are measured. Control cultures either -32lack FKBP12 binding compound or lack FKBP12 binding compound and NGF.
The FKBP12 binding compounds utilized in this invention cause a significant increase in neurite outgrowth over control cultures which lack such compounds in both the presence and absence of NGF.
While I have hereinbefore presented a number of embodiments of this invention, it is apparent that my basic construction can be altered to provide other embodiments which utilize the methods of this invention.
Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments which have been presented hereinbefore by way of example.
a 9
Claims (32)
1. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula B K -N (I) and pharmaceutically acceptable derivatives thereof, wherein A is O, NH, or N-(C1-C4 alkyl); B is hydrogen, CHL-Ar, (C1-C6)-straight or branched Salkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)- *cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (Cl- C6)-alkyl or (C2-C6)-alkenyl, or T L wherein L and Q are independently hydrogen, (Ci-C6)-straight or branched alkyl or (C2-C6)- straight or branched alkenyl; and T is Ar or substituted cyclohexyl with S substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4)- alkenyl; wherein Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-furyl,
3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl and phenyl having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, CF3, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl S...or O-((C2-C4)-straight or branched alkenyl), -benzyl, O-phenyl, amino and phenyl; D is U; E is either oxygen or CH-U, provided that if D is g S. hydrogen, then E is CH-U or if E is oxygen then D is not hydrogen; wherein each U is independently selected from hydrogen, O-(C1-C4)-straight or branched alkyl or O- ((C2-C4)-straight or branched alkenyl), (C1-C6)- straight or branched alkyl or (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)- cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; J is hydrogen or C1 or C2 alkyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a
5-6 membered heterocyclic ring which contains a second heteroatom or heterogroup selected from O, S, SO or SO 2 or J and K are taken together to form a 7-membered heterocyclic ring optionally containing a second heteroatom or heterogroup selected from O, S, SO or SO2; and the stereochemistry at carbon position 1 is R or S; a neurotrophic factor; and a pharmaceutically acceptable carrier. 2. A pharmaceutically acceptable composition comprising: a) affinity for a neurotrophic amount of a compound with FKBP12 having the formula K A j ,N (I) and pharmaceutically acceptable derivatives thereof, wherein A is O, NH, or N-(C1-C4 alkyl); B is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)- cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (Cl- C6)-alkyl or (C2-C6)-alkenyl, or wherein L and Q are independently hydrogen, (C1-C6)- straight or branched alkyl or (C2-C6)-straight or branched alkenyl; and T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4)- alkenyl; wherein Ar is selected from the group consisting of l-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl and phenyl having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, CF 3 (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or.branched alkyl or O-((C2-C4)-straight or branched alkenyl), O-benzyl, O-phenyl, amino and phenyl; D is hydrogen; E is CH-U; wherein each U is independently selected from hydrogen, O-(C1-C4)-straight or branched alkyl or O- ((C2-C4)-straight or branched alkenyl), (C1-C6)- straight or branched alkyl or (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)- cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; J and K are taken together to form a 5-6 membered heterocyclic ring; and the stereochemistry at carbon position 1 is R or S; b) a neurotrophic factor; and c) a pharmaceutically acceptable carrier. 3. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula B K -N IO (I) and pharmaceutically acceptable derivatives thereof, i wherein A is O, NH, or N-(C1-C4 alkyl); B is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)- cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (Cl- C6)-alkyl or (C2-C6)-alkenyl, or T L wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)- straight or branched alkenyl; and T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(Cl-C4)-alkyl or 0-(C2-C4)- alkenyl; wherein Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4- ST pyridyl and phenyl having one to three substituents which are independently selected -Ufrom the group consisting of hydrogen halo, i n sfrom the group consisting of hydrogen, halo, hydroxyl, nitro, CF 3 (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-((C2-C4)-straight or branched alkenyl), O-benzyl, O-phenyl, amino and phenyl; D is U; E is oxygen and D is not hydrogen; wherein each U is independently selected from hydrogen, O-(C1-C4)-straight or branched alkyl or O- ((C2-C4)-straight or branched alkenyl), (C1-C6)- straight or branched alkyl or (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)- cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C 2 -C4)-alkenyl]-Ar or Ar; J and K are taken together to form a 6-membered heterocyclic ring; and the stereochemistry at carbon position 1 is R or S; provided that: e. when A is oxygen, D is l,1-dimethyl-l-propyl, then B is not 3-cyclohexylpropyl, 3-phenylpropyl, or 3- (3',4',5'-trimethoxyphenyl)propyl; when A is oxygen, D is 3 4 ,5-trimethoxyphenyl, then, B is not 4 -(4'-methoxyphenyl)butyl; and when A is oxygen, B is ethyl, then D is not methyl, ethyl, isopropyl, 2-methylpropyl, t-butyl, 1,1-dimethyl- l-propyl, phenyl or benzyl; b) a neurotrophic factor; and c) a pharmaceutically acceptable carrier. 4. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula B K J N I D (I) and pharmaceutically acceptable derivatives thereof, wherein A is O, NH, or N-(C1-C4 alkyl); B is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)- cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (Cl- C6)-alkyl or (C 2 -C6)-alkenyl, or T L wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl; and T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or 0-(C2-C4)- alkenyl; wherein Ar is selected from the group consisting of l-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4- Spyridyl and phenyl having one to three Ssubstituents which are independently selected from the group consisting of hydrogen, halo, i n sfrom the group consisting of hydrogen, halo, hydroxyl, nitro, CF 3 (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-((C2-C4)-straight or branched alkenyl), O-benzyl, O-phenyl, amino and phenyl; D is U; E is 0 and D is not hydrogen; wherein each U is independently selected from hydrogen, O-(C1-C4)-straight or branched alkyl or O- ((C2-C4)-straight or branched alkenyl), (C1-C6)- straight or branched alkyl or (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalky1l or (C5-C7)- i cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; J and K are taken together to form a heterocyclic ring; and the stereochemistry at carbon position 1 is R or S. provided that when: A is oxygen, NH or N-(C1-C4 alkyl); D is (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, or Ar; and Ar is 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2- thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or phenyl; then B is not: i) a (C1-C6)alkyl or (C2-C6)alkenyl chain substituted with substituted or unsubstituted 2-furyl, 3- furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or phenyl; or ii) a (C1-C6)alkyl or (C2-C6)alkenyl chain substituted with (C5-C7)-cycloalkyl; b) a neurotrophic factor; and c) a pharmaceutically acceptable carrier. The composition according to claim 1, wherein in said compound with affinity for FKBP12: A is oxygen; J is hydrogen or C1 or C2 alkyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 5-6 membered heterocyclic ring which contains a second heteroatom or heterogroup selected from O, S, SO or SO 2 and the stereochemistry at carbon position 1 is S.
6. The composition according to claim 2, wherein in said compound with affinity for FKBP12: J and K are taken together to form pyrrolidyl or piperidyl; and E is CH-U; and U is dimethylaminophenyl, methoxyphenyl, dimethoxyphenyl, trimethoxyphenyl, nitrophenyl, furyl, indolyl, pyridyl, or methylenedioxyphenyl.
7. The composition according to claim wherein in said compound with affinity for FKBP12: J and K are taken together to form a 5-6 membered heterocyclic ring which contains a second heteroatom or 9999 heterogroup selected from O, S, SO or SO,; E is oxygen: B is benzyl, naphthyl, tert-butyl, hydrogen, E-3- phenyl-2-methyl-prop-2-enyl, E-3-(4-hydroxyphenyl) 2- methyl-prop-2-enyl, E-3-[trans(4-hydroxycyclohexyl)]-2- methyl-prop-2-enyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclopentylopropyl, E-3-(4-methoxyphenyl)- 2 -methyl-prop-2-enyl, E-3-(3,4-dimethoxyphenyl)-2-methyl-prop-2-enyl or E-3-[cis(4-hydroxycyclohexyl)]- 2 -methyl-prop-2-enyl; and SD is phenyl, methoxyphenyl, cyclohexyl, ethyl, hoxy, nitrobenzyl, thiophenyl, indolyl, furyl, pyridyl, pyridyl-N-oxide, nitrophenyl, fluorophenyl, trimethoxyphenyl or dimethoxyphenyl.
8. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B' N1 W mM G 0 0 *0 *0*0 *00* *0 *00 0*000 OFV (II) and pharmaceutically acceptable derivatives thereof, wherein A' is CH 2 oxygen, NH or N-(C1-C4 alkyl); B' and W are independently: hydrogen, Ar', (C1-C10)-straight or branched alkyl, (C2-C10)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkyl-substituted (C1-C6)-straight or branched alkyl, (C5-C 7 )-cycloalkyl-substituted (C 2 -C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkenyl-substituted (C1-C6)-straight or branched alkyl, (C5-C7)-cycloalkenyl-substituted (C2-C6)-straight or branched alkenyl or(alkyniy, Ar'- substituted-(C1-C6)-straight or branched alkyl, or Ar'- substituted-(C2-C6)-straight or branched alkenyl or alkynyl; wherein, in each case, any one of the CH 2 groups of said alkyl, alkenyl or alkynyl chains may be optionally replaced by a heteroatom selected from the group consisting of O, S, SO, SO 2 N, and NR, wherein R is selected from the group consisting of hydrogen; (C1-C4)-straight or branched alkyl; (C2-C4)-straight or branched alkenyl or alkynyl; (C1-C4) bridging alkyl, wherein a bridge is formed between the nitrogen and a carbon atom of said 42 heteroatom-containing chain to form a ring, and wherein said ring is optionally fused to an Ar' group; or T (ii) wherein QT is hydrogen, (Cl-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl or alkynyl; and *goes T' is Ar' or a 5-7 membered cycloalkyl ring *with substituents at positions 3 and 4, said substituents being independently selected from oxo, hydrogen, hydroxyl, O-(Cl-C4)-alkyl, or GVO0- (C2-C4) -alkenyl; wherein Ar' is selected from phenyl, l-naphthyl, 2-naphthyl, indenyl, azulenyl, S. fluorenyl, anthracenyl, 2-furyl, 3-furyl, fees 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, l,2,3-oxadiazolyl, 1,2,3- triazolyl, 1,3, 4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, l,3,5-triazinyl, 1,3,5- trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo Eb] furanyl, benzo thiophenyl, lH-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H- quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1, 8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, or phenoxazinyl; and wherein Ar' optionally contains one to three substituents which are independently selected from halogen, hydroxyl, hydroxyethyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, O-[(C1-C4)-straight or branched alkyl], 0-[(C2-C4)-straight or branched alkenyl], 0-benzyl, 0-phenyl, 1,2-methylenedioxy, amino, carboxyl, N-[(C1-C5)-straight or branched alkyl or (C2-C5)-straight or branched alkenyl]- carboxamide, N,N-di-[(C1-C5)-straight or branched alkyl or (C2-C5)-straight or branched alkenyl)]carboxamide, N-morpholinocarboxamide, N-benzylcarboxamide, N-thiomorpholinocarboxamide, N-picolinoylcarboxamide, O-X, CH 2 -(CR 2 )q-X, 0 (CR 2 (CR 2 and CR=CH-X; S.i :wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl, or pyrimidyl; and iq is 0-2; G is U'; M is either oxygen or CR-U'; provided that if G is hydrogen, then M is CR-U' or if M is oxygen, then U' is not hydrogen; wherein U' is hydrogen, O-[(C1-C4)-straight or branched alkyl], 0-[(C2-C4)-straight or branched alkenyl], (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)-cycloalkenyl substituted with (Cl-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, [(Cl-C4)-alkyl or (C2-C4)-alkenyl]-Y or Y; wherein Y is selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, 2- pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3- dioxolyl, 2-imidazolinyl, iridazolidinyl, 2H- pyranyl, 4H-pyranyl, piperidyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, quinuclidinyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyricyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3- triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5- trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b] furanyl, benzo[b]thiophenyl, 1H-indazolyl, benzimiazolyl, benzthiazolyl, purinyl, 4H- quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, or phenoxazinyl; and wherein Y optionally contains one to three substituents which are independently selected from halogen, hydroxyl, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-06)-straight or branched alkyl, (C2-CE)-straight or branched alkenyl, O-[(C1-C4)-straight or branched alkyl], O-[(C2-04)-straight or branched alkenyl], O-benzyl, 0-phenyl, 1,2-methylenedioxy, amino, or carboxyl; J' is hydrogen, (01-02) alkyl or benzyl; K' is (01-04)-straight or branched alkyl, benzyl or cyclohexylmethyl; or J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 7-membered heterocyclic ring optionally containing a heteroatom selected from the group consisting of O, S, SO and SO2 or a 5-6 membered heterocyclic ring containing a heteroatom selected from the group consisting of O, S, SO and SO 2 m is 0-3; and wherein said compound is not a compound of formula b) a neurotrophic factor; and c) a pharmaceutically suitable carrier.
9. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): JA' I:N 1 2 W M G (II) and pharmaceutically acceptable derivatives thereof, wherein G, M, W, Ar' and its optional substituents, X, Y and its optional substituents, R, T', q and m are as defined in claim 8; J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 6-membered heterocyclic ring; and wherein said compound is not a compound of formula provided that when m is 0, A and M are oxygen, G is 1,1-dimethyl-l-propyl, and W is 2-phenylethyl, then B' is not 1,l-dimethyl-l-prop-2-enyl, phenyl, cyclohexyl, or 3- (N,N-diallyl)benzamide; and when m is 0, A and M are oxygen, G is tert-butyl, and W is 2-(3',4',5'-trimethoxyphenyl)ethyl, then B' is not phenyl; and b) a neurotrophic factor; c) a pharmaceutically suitable carrier. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B' A' W (II) and pharmaceutically acceptable derivatives thereof, Swherein G, M, W, Ar' and its optional substituents, X, Y and its optional substituents, R, T', q and m are as defined in claim 8; J' and K' are taken together with the nitrogen atom provided at least one of B' or W is independently selected from the group consisting of (C2-C10)-straight or branched alkynyl; (C5-C7)-cycloalkyl substituted (C2-C6)-straight or branched alkynyl; (C5-C7)-cycloalkenyl substituted (C2-C6)-straight or branched alkynyl; and Ar' substituted (C2-C6)-straight or branched alkynyl; and provided that if G is hydrogen, then M is CH-U' or ST if M is oxygen, then G is not hydrogen; b) a neurotrophic factor; and c) a pharmaceutically suitable carrier.
11. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B N1 A W m M G G (II) and pharmaceutically acceptable derivatives thereof, wherein G, M, W, Ar', X, Y and its optional substituents, R, q and m are as defined in claim 8; Ar' contains one to three substituents which are independently selected from the group consisting of or branched alkyl or straight or branched alkenyl] carboxamide, N,N-di-[(C1-C5)-straight or branched alkyl or straight or branched alkenyl)]carboxamide, N-morpholinocarboxamide, N-benzylcarboxamide, N-thiomorpholinocarboxamide, N-picolinoylcarboxamide, O-X, CH 2 -(CH 2 O-(CH 2 (CH 2 and CH=CH-X; J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 5-6 membered heterocyclic ring; and wherein said compound is not a compound of formula provided that at least one of B' or W is Ar', Ar'-substituted (C1-C6)-straight or branched alkyl, and Ar'-substituted (C2-C6)-straight or branched alkenyl or S T alkynyl; and provided that if G is hydrogen, then M is CH-U' or if M is oxygen, then G is not hydrogen; b) a neurotrophic factor; and c) a pharmaceutically suitable carrier.
12. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B' Ni A W *J *G (II) *eeo and pharmaceutically acceptable derivatives thereof, i: wherein G, W, Ar' and its optional substituents, X, Y, R, q and m are as defined in claim 8; M is CH-U'; J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 5-6 membered heterocyclic ring; and wherein said compound is not a compound of formula b) a neurotrophic factor; and c) a pharmaceutically suitable carrier.
13. A pharmaceutically acceptable composition comprising: a) a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B' N1 A W I m M G (II) and pharmaceutically acceptable derivatives thereof, wherein G, W, Ar' and its optional substituents, M, X, Y and its optional substituents, R, q and m are as defined in claim 8; J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 5-membered heterocyclic ring; and wherein said compound is not a compound of formula provided that if G is hydrogen, then M is CH-U' or if M is oxygen, then G is not hydrogen; and provided that when: M is oxygen; A is oxygen, NH or N-(C1-C4 alkyl); G is (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)-cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, or Y; and Y is l-naphthyl, 2-naphthyl, indolyl, 2-furyl, 3- furyl, thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3- pyridyl, 4-pyridyl or phenyl; then (CH 2 B' and W, taken together, do not form: i) substituted or unsubstituted indolyl, 2-furyl, 3- furyl, thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3- pyridyl, 4-pyridyl or phenyl; ii) an alkyl or alkenyl chain substituted with substituted or unsubstituted indolyl, 2-furyl, 3-furyl, thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3 -pyridyl, 4- pyridyl or phenyl; or iii) an alkyl or alkenyl chain substituted with (C5-C7)-cycloalkyl; b) a neurotrophic factor; and c) a pharmaceutically suitable carrier.
14. The composition according to any one of claims 8-13, wherein: B' and W are independently: hydrogen, Ar', (C1-C10)-straight or branched alkyl, (C 2 -C10)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkyl substituted (C1-C6)-straight or branched alkyl, (C 2 -C6)-straight or branched alkenyl or alkynyl, (C 5 -C 7 )-cycloalkenyl substituted (C1-C6)-straight or branched alkyl, (C 2 -C6)-straight or branched alkenyl or alkynyl, or Ar' substituted (C1-C6)-straight or branched alkyl, (C 2 -C6)-straight or branched alkenyl or alkynyl wherein, in each case, any one of the CH 2 groups of said alkyl, alkenyl or alkynyl chains may be optionally replaced by a heteroatom selected from the group consisting of O, S, S SO2; or (ii) Ar' may contain one to three substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or branched alkyl, (C 2 -C6)-straight or branched alkenyl, O-[(C1-C4)-straight or branched alkyl], O-[(C 2 -C4)-straight or branched alkenyl], O-benzyl, ZIRA O-phenyl, 1,2-methylenedioxy, amino and carboxyl; and Y is selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4- thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5- triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, or phenoxazinyl.
15. The composition according to any one of claims 8-13, wherein: at least one of B' or W is independently selected from the group consisting of (C2-C10)-straight or branched alkynyl; (C5-C7)-cycloalkyl substituted (C2-C6)-straight or branched alkynyl; g* (C5-C7)-cycloalkenyl substituted (C2-C6)-straight or branched alkynyl; and Ar' substituted (C2-C6)-straight or branched alkynyl.
16. The composition according to any one of claims 8-13, wherein: at least one of B' or W is independently represented by the formula -(CH 2 2 wherein: Z is independently selected from the group consisting of CH2, O, S, SO, S02, N, and NR; r is 0-4; and s is 0-1.
17. The composition according to any one of claims 8-13, wherein: at least one of B' or W is independently selected from the group consisting of Ar', Ar'-substituted (Cl- C6)-straight or branched alkyl, and Ar'-substituted (C2- C6)-straight or branched alkenyl or alkynyl; and wherein Ar' is substituted with one to three substituents which are independently selected from the group consisting of N-(straight or branched (Cl- or (C2-C5)-alkenyl) carboxamide, N,N-di-(straight or branched (C1-C5)-alkyl or (C2- N-morpholinocarboxamide, N- benzylcarboxamide, N-thiomorpholinocarboxamide, N-picolinoylcarboxamide, O-X, CH 2 -(CH 2 )q-X, O-(CH 2 (CH 2 and CH=CH-X. e
18. The composition according to any of claims o 1-4 or 8-13, wherein said neurotrophic factor is selected from nerve growth factor (NGF), insulin growth factor (IGF) and active truncated derivatives thereof, acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), platelet-derived growth factors (PDGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3) and neurotrophin 4/5
19. The composition according to claim 18, wherein said neurotrophic factor is NGF. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula K A N O D (I) and pharmaceutically acceptable derivatives thereof, wherein A is O, NH, or N-(C1-C4 alkyl); B is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)- cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (Cl- C6)-alkyl or (C2-C6)-alkenyl, or T L V. k wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)- straight or branched alkenyl; and T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4)- alkenyl; wherein Ar is selected from the group consisting of l-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl and phenyl having one to three 7 substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, CF 3 (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-((C2-C4)-straight or branched alkenyl), O-benzyl, O-phenyl, amino and phenyl; D is U; E is either oxygen or CH-U, provided that if D is hydrogen, then E is CH-U or if E is oxygen then D is not hydrogen; wherein each U is independently selected from hydrogen, O-(C1-C4)-straight or branched alkyl or O- ((C2-C4)-straight or branched alkenyl), (C1-C6)- straight or branched alkyl or (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)- cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; J is hydrogen or C1 or C2 alkyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 5-6 membered heterocyclic ring which contains a second heteroatom or heterogroup selected from O, S, SO or SO 2 or J and K are taken together to form a 7-membered heterocyclic ring optionally containing a second heteroatom or heterogroup selected from O, S, SO or SO 2 and the stereochemistry at carbon position 1 is R or S.
21. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula K A J 0 D (I) and pharmaceutically acceptable derivatives thereof, wherein A is O, NH, or N-(C1-C4 alkyl); *o B is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)- cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (Cl- C6)-alkyl or (C2-C6)-alkenyl, or 0 5 wherein L and Q are independently hydrogen, (C1-C6)- straight or branched alkyl or (C2-C6)-straight or branched alkenyl; and T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or 0-(C2-C4)- alkenyl; wherein Ar is selected from the group Sconsisting of l-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl and phenyl having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, CF 3 (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-((C2-C4)-straight or branched alkenyl), O-benzyl, O-phenyl, amino and phenyl; D is hydrogen; E is CH-U; wherein each U is independently selected from i: hydrogen, O-(C1-C4)-straight or branched alkyl or O- ((C2-C4)-straight or branched alkenyl), (C1-C6)- 0o o straight or branched alkyl or (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)- cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; J and K are taken together to form a 5-6 membered heterocyclic ring; and the stereochemistry at carbon position 1 is R or S.
22. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula B K N -D (I) and pharmaceutically acceptable derivatives thereof, wherein A is O, NH, or N-(C1-C4 alkyl); B is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)- cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (Cl- C6)-alkyl or (C2-C6)-alkenyl, or T L wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)- straight or branched alkenyl; and T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or 0-(C2-C4)- alkenyl; wherein Ar is selected from the group consisting of l-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl and phenyl having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, CF 3 (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-((C2-C4)-straight or branched alkenyl), O-benzyl, O-phenyl, amino and phenyl; D is U; E is oxygen and D is not hydrogen; wherein each U is independently selected from ST hydrogen, O-(C1-C4)-straight or branched alkyl or O- b C ((C2-C4)-straight or branched alkenyl), (C1-C6)- straight or branched alkyl or (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)- cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; J and K are taken together to form a 6-membered heterocyclic ring; and the stereochemistry at carbon position 1 is R or S; provided that: when A is oxygen, D is 1,1-dimethyl-l-propyl, then B is not 3 -cyclohexylpropyl, 3-phenylpropyl, or 3- (3',4',5'-trimethoxyphenyl)propyl; when A is oxygen, D is 3 ,4,5-trimethoxyphenyl, then, B is not 4 -(4'-methoxyphenyl)butyl; and when A is oxygen, B is ethyl, then D is not methyl, ethyl, isopropyl, 2-methylpropyl, t-butyl, 1,1-dimethyl- 1-propyl, phenyl or benzyl.
23. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula eeo B D K A (I) cand pharmaceutically acceptable derivatives thereof, wherein A is O, NH, or N-(C1-C4 alkyl); 59 B is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)- cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (C1- C6)-alkyl or (C2-C6)-alkenyl, or T L wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl; and T is Ar or substituted cyclohexyl with i substituents at positions 3 and 4 which are *independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4)- alkenyl; wherein Ar is selected from the group consisting of l-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl and phenyl having one to three 0 substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, CF 3 (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched :i alkenyl, O-(C1-C4)-straight or branched alkyl or O-((C2-C4)-straight or branched alkenyl), O-benzyl, O-phenyl, amino and phenyl; D is U; E is O and D is not hydrogen; wherein each U is independently selected from hydrogen, O-(C1-C4)-straight or branched alkyl or O- ((C 2 -C4)-straight or branched alkenyl), (C1-C6)- straight or branched alkyl or (C 2 -C6)-straight or Sbranched alkenyl, (C5-C 7 )-cycloalkyl or (C5-C7)- cycloalkenyl substituted with (C1-C 4 )-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; J and K are taken together to form a heterocyclic ring; and the stereochemistry at carbon position 1 is R or S. provided that when: A is oxygen, NH or N-(C1-C4 alkyl); D is (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, or Ar; and Ar is l-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2- thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or phenyl; then B is not: i) a (C1-C6)alkyl or (C2-C6)alkenyl chain substituted with substituted or unsubstituted 2-furyl, 3- furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or o phenyl; or ii) a (C1-C6)alkyl or (C2-C6)alkenyl chain substituted with (C5-C7)-cycloalkyl.
24. The method according to claim 20, wherein in said compound with affinity for FKBP12: A is oxygen; J is hydrogen or C1 or C2 alkyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 5-6 membered heterocyclic ring which contains a second heteroatom or heterogroup selected from O, S, SO or SO2; and the stereochemistry at carbon position 1 is S. The method according to claim 21, wherein in said compound with affinity for FKBP12: SJ and K are taken together to form pyrrolidyl or iperidyl; and E is CH-U; and U is dimethylaminophenyl, methoxyphenyl, dimethoxyphenyl, trimethoxyphenyl, nitrophenyl, furyl, indolyl, pyridyl, or methylenedioxyphenyl.
26. The method according to claim 24, wherein in said compound with affinity for FKBP12: J and K are taken together to form a 5-6 membered heterocyclic ring which contains a second heteroatom or heterogroup selected from O, S, SO or SO 2 E is oxygen; B is benzyl, naphthyl, tert-butyl, hydrogen, E-3- phenyl-2-methyl-prop-2-enyl, E-3-(4-hydroxyphenyl) 2- methyl-prop-2-enyl, E-3-[trans(4-hydroxycyclohexyl)]-2- methyl-prop-2-enyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclopentylopropyl, E-3-(4-methoxyphenyl)-2-methyl-prop-2-enyl, 4-dimethoxyphenyl)-2-methyl-prop-2-enyl or E-3-[cis(4-hydroxycyclohexyl) 2 -methyl-prop-2-enyl; and D is phenyl, methoxyphenyl, cyclohexyl, ethyl, methoxy, nitrobenzyl, thiophenyl, indolyl, furyl, pyridyl, pyridyl-N-oxide, nitrophenyl, fluorophenyl, trimethoxyphenyl or dimethoxyphenyl. ~27. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B' N )2A')W m G and pharmaceutically acceptable derivatives thereof, wherein A' is CH 2 oxygen, NH or N-(C1-C4 alkyl); B' and W are independently: hydrogen, Ar', (C1-C10)-straight or branched alkyl, (C2-C10)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkyl-substituted (C1-C6)-straight or branched alkyl, (C5-C7)-cycloalkyl substituted (C2-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkenyl-substituted (C1-C6)-straight or branched alkyl, (C5-C7)-cycloalkenyl-substituted (C2-C6)-straight or branched alkenyl or alkynyl, Ar'- substituted-(C1-C6)-straight or branched alkyl, or Ar'- substituted-(C2-C6)-straight or branched alkenyl or alkynyl; wherein, in each case, any one of the CH 2 groups of said alkyl, alkenyl or alkynyl chains may be optionally replaced by a heteroatom selected from the group consisting of O, S, SO, SO 2 N, and NR, wherein R is selected from the group consisting of hydrogen; (C1-C4)-straight or branched alkyl; (C2-C4)-straight or branched alkenyl or alkynyl; (C1-C4) bridging alkyl, wherein a bridge is formed between the nitrogen and a carbon atom of said heteroatom-containing chain to form a ring, and wherein said ring is optionally fused to an Ar' group; or T (ii) wherein Q' is hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl or alkynyl; and T' is Ar' or a 5-7 membered cycloalkyl ring with substituents at positions 3 and 4, said 63 substituents being independently selected from oxo, hydrogen, hydroxyl, O-(Cl-C4)-alkyl, or 0-(C2-C4)-alkenyl; wherein Ar' is selected from phenyl, l-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3- triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, l, 3 ,5-triazinyl, 1,3,5- trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[bithiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H- *quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, or phenoxazinyl; and wherein Ar' optionally contains one to three substituents which are independently selected from halogen, hydroxyl, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, (Cl-CG)-straight or branched alkyl, (C2-CG)-straight or branched alkenyl, 0 -[(Cl-C4)-straight or branched alkyl], O-[(C2-C4)-straight or branched alkenyl], O-benzyl, 0-phenyl, 1,2-methylenedioxy, amino, carboxyl, N-[(Cl-C5)-straight or branched alkyl or (C 2 -C5)-straight or branched alkenyl]- carboxamide, N,N-di-[(C1-05)-straight or branched alkyl or (C2-C5)-straight or branched alkenyl)Icarboxamide, N-morpholinocarboxamide, N-benzylcarboxamide, SN-thiomorpholinocarboxamide, N-picolinoylcarboxamide, O-X, CR 2 -(CR 2 )q-X, 0 (CR 2 (CR 2 and CR=CR-X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, isoxazoyl, 2-methyithiazoyl, thiazoyl, 2-thienyl, 3-thienyl, or pyrimidyl; and q is 0-2; G is U'; M is either oxygen or CR-U'; provided that if G is hydrogen, then M is CR-U' or if M is oxygen, then U' is not hydrogen; wherein U' is hydrogen, O-[(C1-C4)-straight or branched alkyl], O-[(C2-C4)-straight or branched alkenyl], (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)-cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Y or Y; wherein Y is selected from the group *i consisting of phenyl, l-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, 2- pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3- dioxolyl, 2-imidazolinyl, imidazolidinyl, 2H- pyranyl, 4R-pyranyl, piperidyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, quinuclidinyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3- triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5- trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H- quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, or phenoxazinyl; and wherein Y optionally contains one to three substituents which are independently selected from halogen, hydroxyl, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, O-[(C1-C4)-straight or branched alkyl], O-[(C2-C4)-straight or branched alkenyl], O-benzyl, O-phenyl, 1,2-methylenedioxy, amino, or carboxyl; J' is hydrogen, (C1-C2) alkyl or benzyl; K' is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylmethyl; or J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 7-membered heterocyclic ring optionally containing a heteroatom selected from the group consisting of O, S, SO and SO 2 or a 5-6 membered heterocyclic ring containing a heteroatom selected from the group consisting of O, S, SO and SO 2 m is 0-3; and wherein said compound is not a compound of formula
28. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B' J A' N W O m M G (II) and pharmaceutically acceptable derivatives thereof, wherein G, M, W, Ar' and its optional substituents, X, Y and its optional substituents, R, T', q and m are as defined in claim 27; J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 6-membered heterocyclic ring; and wherein said compound is not a compound of formula provided that when m is 0, A and M are oxygen, G is 1,1-dimethyl-l-propyl, and W is 2-phenylethyl, then B' is not 1,1-dimethyl-l-prop-2-enyl, phenyl, cyclohexyl, or 3- oo (N,N-diallyl)benzamide; and when m is 0, A and M are oxygen, G is tert-butyl, and W is 2 -(3',4',5'-trimethoxyphenyl)ethyl, then B' is not phenyl.
29. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound K' B with affinity for FKBP12 having J /N 1 A 2 the formula (II): m 0^\^M r~ (II) and pharmaceutically acceptable derivatives thereof, wherein G, M, W, Ar' and its optional substituents, X, Y and its optional substituents, R, T', q and m are as defined in claim 27; J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 5-6 membered heterocyclic ring; and wherein said compound is not a compound of formula provided at least one of B' or W is independently selected from the group consisting of (C2-C10)-straight or branched alkynyl; (C5-C7)-cycloalkyl substituted (C2-C6)-straight or branched alkynyl; (C5-C7)-cycloalkenyl substituted (C2-C6)-straight or branched alkynyl; and Ar' substituted (C2-C6)-straight or S. branched alkynyl; and provided that if G is hydrogen, then M is CH-U' or if M is oxygen, then G is not hydrogen. eeo 30. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B' JN 2 W itm G (II) and pharmaceutically acceptable derivatives thereof, wherein G, M, W, Ar', X, Y and its optional substituents, R, q and m are as defined in claim 27; Ar' contains one to three substituents which are independently selected from the group consisting of or branched alkyl or straight or branched alkenyl] carboxamide, or branched alkyl or straight or branched alkenyl)]carboxamide, N-morpholinocarboxamide, N-benzylcarboxamide, N-thiomorpholinocarboxamide, N-picolinoylcarboxamide, O-X, CH 2 -(CH 2 O-(CH2)q-X, (CH2)q-O-X, and CH=CH-X; J' and K' are taken together with the nitrogen atom *:and the carbon atom to which they are respectively bound to form a 5-6 membered heterocyclic ring; and wherein said compound is not a compound of formula provided that at least one of B' or W is Ar', Ar'-substituted (C-C)-straight or branched alkyl, and Ar'-substituted (C1-C6)-straight or branched alkenyl, and Ar'-substituted (C2-C6)-straight or branched alkenyl or alkynyl; and o000 provided that if G is hydrogen, then M is CH-U' or if M is oxygen, then G is not hydrogen.
31. A method for stimulating neurite growth in *0 nerve cells comprising the step of contacting said nerve cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II): K' B Ni (II) J A 2- W m b 6(II) OFFIG 69 and pharmaceutically acceptable derivatives thereof, wherein G, W, Ar' and its optional substituents and its optional substituents, X, Y, R, T', q and m are as defined in claim 27; M is CH-U'; J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 5-6 membered heterocyclic ring; and wherein said compound is not a compound of formula
32. A method for stimulating neurite growth in nerve cells comprising the step of contacting said nerve S* cells with a composition comprising a neurotrophic amount of a compound with affinity for FKBP12 having the formula (II) K' B' N I" A'm W a m i* is G (II) and pharmaceutically acceptable derivatives thereof, wherein G, W, Ar' and its optional substituents, M, X, Y and its optional substituents, R, q and m are as defined in claim 27; J' and K' are taken together with the nitrogen atom and the carbon atom to which they are respectively bound to form a 5-membered heterocyclic ring; and wherein said compound is not a compound of formula provided that if G is hydrogen, then M is CH-U' or WS~ if M is oxygen, then G is not hydrogen; and provided that when: M is oxygen; A is oxygen, NH or N-(C1-C4 alkyl); G is (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl or (C5-C7)-cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, or Y; and Y is 1-naphthyl, 2-naphthyl, indolyl, 2-furyl, 3- furyl, thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3- pyridyl, 4-pyridyl or phenyl; then (CH 2 B' and W, taken together, do not form: i) substituted or unsubstituted indolyl, 2-furyl, 3- furyl, thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3- pyridyl, 4-pyridyl or phenyl;. ii) an alkyl or alkenyl chain substituted with substituted or unsubstituted indolyl, 2-furyl, 3-furyl, thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl or phenyl; or iii) an alkyl or alkenyl chain substituted with (C5-C7)-cycloalkyl.
33. The method according to any one of claims .*27-32, wherein in said compound with affinity for FKBP12: B' and W are independently: hydrogen, Ar', (C1-C10)-straight or branched alkyl, (C2-C10)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkyl substituted (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkenyl substituted (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, or Ar' substituted (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl wherein, in each case, any one of the CH 2 groups of said alkyl, alkenyl or alkynyl chains may be optionally replaced by a heteroatom IUSy selected from the group consisting of O, S, SO, SO2; or I 71 T (ii) Ar' may contain one to three substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, (Cl-CG)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, O-[(C1-04)-straight or branched alkyl], O-[(C2-C4)-straight or branched alkenyl], O-benzyl, 0-phenyl, 1,2-methylenedioxy, amino and carboxyl; and Y is selected from the group consisting of phenyl, l-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4- thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5- triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thiophenyl, lH-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, or phenoxazinyl.
34. The method according to claim 32, wherein- in said compound with affinity for FKBP12: at least one of B' or W is independently selected from the group consisting of (C2-C1O)-straight or branched alkynyl; (C5-C7)-cycloalkyl substituted (C2-CG)-straight or branched alkynyl; Zp (C5-C7)-cycloalkenyl substituted (C 2 -CG)-straight or 72 0 F1C~ branched alkynyl; and Ar' substituted (C2-C6)-straight or branched alkynyl. The method according to claim 32, wherein in said compound with affinity for FKBP12: at least one of B' or W is independently represented by the formula -(CH 2 2 wherein: Z is independently selected from the group consisting of CH 2 O, S, SO, SO 2 N, and NR; r is 0-4; and s is 0-1.
36. The method according to claim 32, wherein in said compound with affinity for FKBP12: S at least one of B' or W is independently selected from the group consisting of Ar', Ar'-substituted (Cl- C6)-straight or branched alkyl, and Ar'-substituted (C2- :i C6)-straight or branched alkenyl or alkynyl; and wherein Ar' is substituted with one to three substituents which are independently selected from the group consisting of N-(straight or branched (Cl- or (C2-C5)-alkenyl) carboxamide, N,N-di-(straight or branched (C1-C5)-alkyl or (C2- C5)-alkenyl)carboxamide, N-morpholinocarboxamide, N- benzylcarboxamide, N-thiomorpholinocarboxamide, N-picolinoylcarboxamide, O-X, CH 2 -(CH 2 )q-X, O-(CH 2 (CH 2 and CH=CH-X.
37. The method according to any one of claims 20-23 or 27-32, wherein said method comprises the additional step of contacting said nerve cells with a neurotrophic factor.
38. The method according to claim 37, wherein rUiSsaid neurotrophic factor is selected from nerve growth Sctor (NGF), insulin growth factor (IGF) and active uncated derivatives thereof, acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), platelet-derived growth factors (PDGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3) and neurotrophin 4/5 (NT-
39. The method according to claim 38, wherein said neurotrophic factor is NGF. The method according to any one of claims 20-23 or 27-32, wherein said method is used to treat a patient who is suffering from or has suffered from Alzheimer's disease, Parkinson's disease, ALS, stroke and ischemia associated with stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, :sciatic crush, spinal cord injuries or facial nerve crush.
41. The method according to claim 37, wherein said method is used to treat a patient who is suffering from or has suffered from Alzheimer's disease, Parkinson's disease, ALS, stroke and ischemia associated with stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, sciatic crush, spinal cord injuries or facial nerve crush. DATED this i 7 t Day of September 2002 Vertex Pharmaceuticals Incorporated By their Patent Attorneys CULLEN CO
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU43801/00A AU757406B2 (en) | 1995-06-08 | 2000-07-03 | Methods and compositions for stimulating neurite growth |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US486004 | 1995-06-08 | ||
| AU61119/96A AU6111996A (en) | 1995-06-08 | 1996-06-06 | Methods and compositions for stimulating neurite growth |
| AU43801/00A AU757406B2 (en) | 1995-06-08 | 2000-07-03 | Methods and compositions for stimulating neurite growth |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU61119/96A Division AU6111996A (en) | 1995-06-08 | 1996-06-06 | Methods and compositions for stimulating neurite growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4380100A AU4380100A (en) | 2000-09-07 |
| AU757406B2 true AU757406B2 (en) | 2003-02-20 |
Family
ID=3746179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU43801/00A Ceased AU757406B2 (en) | 1995-06-08 | 2000-07-03 | Methods and compositions for stimulating neurite growth |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU757406B2 (en) |
-
2000
- 2000-07-03 AU AU43801/00A patent/AU757406B2/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| PROC.NATL.ACAD.SCI.USA, VOL.91,P 3191-3195 APRIL 1994 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4380100A (en) | 2000-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6124328A (en) | Methods and compositions for stimulating neurite growth | |
| ES2206753T3 (en) | METHODS AND COMPOSITIONS TO STIMULATE THE GROWTH OF NEURITES. | |
| EA001481B1 (en) | Rotamase enzyme activity inhibitors | |
| JP2001503778A (en) | Methods and compositions for stimulating neurite outgrowth using compounds having affinity for FKBP12 in combination with neurotrophic factors | |
| AU757406B2 (en) | Methods and compositions for stimulating neurite growth | |
| JP2006504717A (en) | Piperazine and piperazine derivatives for the treatment of neurological diseases | |
| JP2006504717A5 (en) | ||
| JP2004536085A (en) | Acylated piperazine and piperidine derivatives useful for treating neuronal injury | |
| HK1094420A (en) | Compositions for stimulating neurite growth | |
| AU6111996A (en) | Methods and compositions for stimulating neurite growth | |
| IL136118A (en) | Compositions for stimulating neurite growth | |
| MXPA97009829A (en) | Methods and compositions to stimulate the growth of neur | |
| JP2002502355A (en) | Methods and compositions for stimulating the growth of neurites | |
| MXPA99004419A (en) | Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors | |
| HK1022851B (en) | Methods and compositions for stimulating neurite outgrowth | |
| MXPA98003356A (en) | Inhibitors of the activity of enzima rotam | |
| MXPA99004421A (en) | Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |